These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38713123)

  • 1. Benefit-Cost Analysis of the HHS COVID-19 Campaign: April 2021-March 2022.
    Turner S; Kranzler EC; Trigger S; Kearsley A; Luchman JN; Williams CJ; Denison B; Dahlen H; Kim JC; Bennett M; Nighbor T; Beleche T; Hoffman L; Peck J
    Am J Prev Med; 2024 Aug; 67(2):258-264. PubMed ID: 38713123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Initial Relationship Between the United States Department of Health and Human Services' Digital COVID-19 Public Education Campaign and Vaccine Uptake: Campaign Effectiveness Evaluation.
    Williams CJ; Kranzler EC; Luchman JN; Denison B; Fischer S; Wonder T; Ostby R; Vines M; Weinberg J; Petrun Sayers EL; Kurti AN; Trigger S; Hoffman L; Peck JFA
    J Med Internet Res; 2023 May; 25():e43873. PubMed ID: 36939670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Return on investment: a fuller assessment of the benefits and cost savings of the US publicly funded family planning program.
    Frost JJ; Sonfield A; Zolna MR; Finer LB
    Milbank Q; 2014 Dec; 92(4):696-749. PubMed ID: 25314928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Strategies for Transitioning to Annual SARS-CoV-2 Vaccination Campaigns in the United States.
    Wells CR; Pandey A; Moghadas SM; Fitzpatrick MC; Singer BH; Galvani AP
    Ann Intern Med; 2024 May; 177(5):609-617. PubMed ID: 38527289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccinations Against COVID-19 May Have Averted Up To 140,000 Deaths In The United States.
    Gupta S; Cantor J; Simon KI; Bento AI; Wing C; Whaley CM
    Health Aff (Millwood); 2021 Sep; 40(9):1465-1472. PubMed ID: 34406840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct impact of COVID-19 vaccination in Chile: averted cases, hospitalizations, ICU admissions, and deaths.
    Brault A; Hart A; Uribe P; Prado J; San Martín J; Maass A; Canals M
    BMC Infect Dis; 2024 May; 24(1):467. PubMed ID: 38698324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness Analysis of The Real Cost Campaign's Effect on Smoking Prevention.
    MacMonegle AJ; Nonnemaker J; Duke JC; Farrelly MC; Zhao X; Delahanty JC; Smith AA; Rao P; Allen JA
    Am J Prev Med; 2018 Sep; 55(3):319-325. PubMed ID: 30122214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling the potential economic benefits of an oral SARS-CoV-2 vaccine during an outbreak of COVID-19.
    Patenaude B; Ballreich J
    BMC Public Health; 2022 Sep; 22(1):1792. PubMed ID: 36131266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lives and Costs Saved by Expanding and Expediting Coronavirus Disease 2019 Vaccination.
    Bartsch SM; Wedlock PT; O'Shea KJ; Cox SN; Strych U; Nuzzo JB; Ferguson MC; Bottazzi ME; Siegmund SS; Hotez PJ; Lee BY
    J Infect Dis; 2021 Sep; 224(6):938-948. PubMed ID: 33954775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Return on Investment of the COVID-19 Vaccination Campaign in New York City.
    Sah P; Vilches TN; Moghadas SM; Pandey A; Gondi S; Schneider EC; Singer J; Chokshi DA; Galvani AP
    JAMA Netw Open; 2022 Nov; 5(11):e2243127. PubMed ID: 36409495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost of COVID-19 vaccine delivery in nine States in Nigeria via the U.S. Government Initiative for Global Vaccine Access.
    Noh DH; Darwar R; Uba BV; Gab-Deedam S; Yani S; Jimoh A; Waziri N; David J; Amoo B; Atobatele S; Dimas J; Fadahunsi R; Sampson S; Simple E; Ugbenyo G; Wisdom M; Asekun A; Pallas SW; Ikwe H
    BMC Health Serv Res; 2024 Oct; 24(1):1232. PubMed ID: 39402600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating deaths averted and cost per life saved by scaling up mRNA COVID-19 vaccination in low-income and lower-middle-income countries in the COVID-19 Omicron variant era: a modelling study.
    Savinkina A; Bilinski A; Fitzpatrick M; Paltiel AD; Rizvi Z; Salomon J; Thornhill T; Gonsalves G
    BMJ Open; 2022 Sep; 12(9):e061752. PubMed ID: 36100306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the "We Can Do This" Campaign Paid Media and COVID-19 Vaccination Uptake, United States, December 2020-January 2022.
    Denison B; Dahlen H; Kim JC; Williams C; Kranzler E; Luchman JN; Trigger S; Bennett M; Nighbor T; Vines M; Petrun Sayers EL; Kurti AN; Weinberg J; Hoffman L; Peck J
    J Health Commun; 2023 Sep; 28(9):573-584. PubMed ID: 37528606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Public health impact of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) in the first year of rollout in the United States.
    Di Fusco M; Marczell K; Deger KA; Moran MM; Wiemken TL; Cane A; de Boisvilliers S; Yang J; Vaghela S; Roiz J
    J Med Econ; 2022; 25(1):605-617. PubMed ID: 35574613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.
    Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Public health impact and economic value of booster vaccination with Pfizer-BioNTech COVID-19 vaccine, bivalent (Original and Omicron BA.4/BA.5) in the United States.
    Di Fusco M; Marczell K; Thoburn E; Wiemken TL; Yang J; Yarnoff B
    J Med Econ; 2023; 26(1):509-524. PubMed ID: 36942976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of COVID-19 vaccination in the US: Averted burden of SARS-COV-2-related cases, hospitalizations and deaths.
    Yamana TK; Galanti M; Pei S; Di Fusco M; Angulo FJ; Moran MM; Khan F; Swerdlow DL; Shaman J
    PLoS One; 2023; 18(4):e0275699. PubMed ID: 37098043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cost-effectiveness analysis of South Africa's COVID-19 vaccination programme.
    Edoka I; Silal S; Jamieson L; Meyer-Rath G
    Vaccine; 2024 Aug; 42(20):125988. PubMed ID: 38824084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling the potential public health and economic impact of different COVID-19 booster dose vaccination strategies with an adapted vaccine in the United Kingdom.
    Harrison C; Butfield R; Yarnoff B; Yang J
    Expert Rev Vaccines; 2024; 23(1):730-739. PubMed ID: 39072472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimated global public health and economic impact of COVID-19 vaccines in the pre-omicron era using real-world empirical data.
    Yang J; Vaghela S; Yarnoff B; De Boisvilliers S; Di Fusco M; Wiemken TL; Kyaw MH; McLaughlin JM; Nguyen JL
    Expert Rev Vaccines; 2023; 22(1):54-65. PubMed ID: 36527724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.